Nanovery
PrivateLast Round
Accelerator
Jun 10, 2025
Total Funding Raised
$5.43M
Company Overview
Nanovery operates in Healthcare & Life Sciences and is based in Newcastle upon Tyne. Its latest recorded funding round was an Accelerator round in June 2025.
Nanovery is a biotechnology company that develops a proprietary Nucleic Acid Nanorobotics (NANs) platform for precise RNA therapeutic analysis, biomarker quantification, and early disease detection.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Biotech Equipment
Business Model
B2B
Customer Profile
Services & Consulting, Usage-Based SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nanovery Comparables
Compare Nanovery with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Moirai Biodesign | 78% | |
| InvenireX | 75% | |
| Esya Labs | 70% |
For institutional investors. Book with your work email.
Nanovery Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Accelerator | Jun 10, 2025 | ||||
| Seed | Apr 10, 2025 | ||||
| Grant | Apr 1, 2025 | ||||
| Grant | Apr 12, 2023 | ||||
| Seed | Apr 12, 2023 | ||||
Grant | Sep 1, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Nanovery Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovate UK | Grant |
| Innovate UK | Grant |
| Northstar Ventures | Seed |
| Prostate Cancer Research | Seed |
| BioTools Innovator | Accelerator |
| SFC Capital | Seed |
| JRH Alternatywna Spółka Inwestycyjna | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 22, 2026
Monthly visitors increased 551% MoM, reaching 2.1K.
- Apr 20, 2026
Monthly visitors grew 135% MoM, reaching 1K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withOct 13, 2026
Nanovery partners with The University of Edinburgh and Edinburgh hospitals on a project exploring disease biomarkers in patients’ blood in United Kingdom.
For institutional investors. Book with your work email.
Nanovery Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Nanovery's valuation, stock price, and market status.
Is Nanovery a public or private company?
Nanovery is a private company.
What is the current stock price of Nanovery?
Nanovery is a private company, so its shares have no public market price. Caplight tracks Nanovery's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Nanovery worth (valuation)?
Valuation information for Nanovery is not publicly available.
Can I buy Nanovery stock?
Nanovery shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Nanovery's last funding round?
Nanovery's most recent funding round was Accelerator on June 10, 2025.
Who are the main investors in Nanovery?
Key investors in Nanovery include Innovate UK, Innovate UK, Northstar Ventures, Prostate Cancer Research, BioTools Innovator.
Will Nanovery IPO soon?
No public IPO plans have been announced for Nanovery.
How can I track Nanovery secondary market activity?
Caplight tracks bids, offers, and trades in Nanovery's shares on secondary markets.